Tafamidis

(Vyndamax®)

Vyndamax®

Drug updated on 11/14/2023

Dosage FormCapsule (oral: 61 mg)
Drug ClassTransthyretin stabilizers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyndamax (tafamidis) Prescribing Information.2021Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines